Cancer hallmark–based gene sets and personalized medicine for patients with stage II colon cancer
Menée sur 162 patients atteints d'un cancer colorectal de stade II, puis validée sur 843 patients complémentaires, cette étude évalue la performance d'un groupe de 8 signatures, basées chacune sur l'expression de 30 gènes, pour prédire le risque de récidive et le bénéfice, en termes de survie, d'une chimiothérapie adjuvante
One of the most controversial areas of clinical oncology is the postoperative management of patients with stage II colon cancer. The promise of personalized medicine and tailored decision making has been taunting clinicians in this disease setting for the past decade. Multiple efforts to identify molecular signatures that provide an accurate and personalized assessment of the risk of relapse (ie, prognostic signatures) and an accurate and personalized assessment of the benefit from adjuvant chemotherapy (ie, predictive signatures) have been made, but this holy grail combination of personalized oncology has remained elusive.
JAMA Oncology , éditorial, 2015